Afinitor
AstraZeneca diabetes drug approved for use in Scotland
November 11, 2014Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2
The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …
Novartis reports healthy profit
April 25, 2014Sales and Marketing Afinitor, Gleevec, Glivec, Novartis, Q1, lilly
Multiple sclerosis drug Gilenya and cancer treatment Afinitor were among the biggest sellers for Novartis, as the Swiss company’s net …
Novartis sees profit slip
October 23, 2013Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya
Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …
Late-stage failure for Afinitor
August 8, 2013Research and Development, Sales and Marketing Afinitor, Cancer, Novartis, liver
Novartis’ oncology programme has received a blow with the news that Afinitor has failed to help patients live longer in …
Novartis’ Afinitor fails NICE test
July 8, 2013Sales and Marketing Afinitor, NHS, NICE, Novartis
Novartis’ breast cancer drug Afinitor (everolimus) has been knocked back by NICE as “it is not good value for money”. …
Afinitor’s new UK indication launched
September 20, 2012Sales and Marketing Afinitor, CHMP, Novartis, breast cancer
Novartis’ cancer drug Afinitor has been made available in the UK for patients with the most common form of advanced …
Afinitor recommended in Europe for breast cancer
June 22, 2012Sales and Marketing Afinitor, CHMP, Cancer, Novartis, breast
A European committee is recommending Novartis’ Afinitor to treat women with a certain type of breast cancer. The CHMP says …
Breast cancer treatment – the next advances
February 7, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, CDF, Lorena Tonarelli, T-DM1, breast cancer, pertuzumab
When a close member of my family was diagnosed with breast cancer, the doctors didn’t give us much hope. They …
Novartis’ brain tumour drug Votubia launched in UK
September 29, 2011Sales and Marketing Afinitor, Votubia
Novartis has launched its orphan drug Votubia in the UK for patients with a rare type of brain tumour. Votubia …
Afinitor expands European licence
September 5, 2011Sales and Marketing Afinitor, Novartis, Pancreatic cancer
Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …
Afinitor poised to realise blockbuster ambitions?
July 25, 2011Sales and Marketing Afinitor, Cancer, Novartis
Novartis’ Afinitor may be set to make good on its blockbuster promise after receiving European backing for its second licence …
Afinitor stops tumour growth in advanced breast cancer
July 5, 2011Manufacturing and Production, Research and Development Afinitor, Novartis, Votubia, advanced breast cancer
Novartis’ Afinitor has impressed in a late-stage trial by increasing survival in women with advanced breast cancer. The phase III …
Novartis’ Afinitor wins landmark US approval
May 6, 2011Sales and Marketing Afinitor, Novartis
Novartis’ Afinitor has been approved in the US for the treatment of progressive neuroendocrine tumours of pancreatic origin (PNET) in …
NICE unimpressed with Novartis’ patient access scheme
April 19, 2011Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis
Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
